Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Preferred Stock Liabilities (2023 - 2024)

Camp4 Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $162.1 million for Q3 2024.

  • For Q3 2024, Preferred Stock Liabilities changed 0.0% year-over-year to $162.1 million; the TTM value through Sep 2024 reached $162.1 million, changed 0.0%, while the annual FY2023 figure was $162.1 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q3 2024 was $162.1 million at Camp4 Therapeutics, roughly flat from $162.1 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $162.1 million in Q3 2023 and bottomed at $162.1 million in Q3 2023.